Department of Microbial, Cellular and Molecular Biology, College of Natural Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
JCO Glob Oncol. 2021 Feb;7:277-288. doi: 10.1200/GO.20.00391.
In developing countries, Hodgkin lymphoma (HL) affects the young population. In Ethiopia, nearly 70% of the population are < 35 years of age. Therefore, this study aimed to elucidate the age distribution, histopathologic patterns, clinical characteristics and treatment outcomes of HL in Ethiopia.
Data from clinical records of 133 consecutive patients with HL between 2014 and 2019 were reviewed and collected. Formalin-fixed paraffin-embedded tissue blocks of HL cases were collected and used for subtype classification.
A total of 68.4% (91) of the patients were male; male-to-female ratio was 2.2:1. The median age was 22 years. The age distribution was 57.1% (76), 30.8% (41), and 2.3% (3) for the age groups (10-29), (30-59), and (60-69) years, respectively. Thirteen percent (12) were associated with HIV. The majority of the cases, 50.4% (67), were of the mixed-cellularity (MCCHL) subtypes and 30% (40) nodular-sclerosis (NSCCHL). Most HIV-associated cases (60%, 6) were of the MCHL subtype. The 4-year overall survival (OS) was 83.1%. The 4-year OS of early-stage patients was 100% and advanced-stage patients with low-risk (International Prognostic Score [IPS] ≤ 2) and high-risk (IPS ≥ 3) were 94.1% and 62.9%, respectively. All patients who received combined-therapy survived, whereas those who received doxorubicin, bleomycin, vinblastine, and dacarbazine only showed a 4-year OS rate of 77.9%.
HL affects the youngest and most productive population in Ethiopia. The treatment outcome is favorable in both HIV-associated and non-HIV-associated HL. However, the study population was likely a highly selected group as the majority of the Ethiopian population do not have access to specialized care.
在发展中国家,霍奇金淋巴瘤(HL)影响年轻人群。在埃塞俄比亚,近 70%的人口年龄小于 35 岁。因此,本研究旨在阐明 HL 在埃塞俄比亚的年龄分布、组织病理学模式、临床特征和治疗结果。
回顾性分析了 2014 年至 2019 年期间 133 例连续 HL 患者的临床记录并收集了数据。收集 HL 病例的福尔马林固定石蜡包埋组织块用于亚型分类。
共 68.4%(91 例)的患者为男性;男女比例为 2.2:1。中位年龄为 22 岁。年龄分布为 57.1%(76 例)、30.8%(41 例)和 2.3%(3 例),年龄组分别为(10-29)岁、(30-59)岁和(60-69)岁。13%(12 例)与 HIV 相关。大多数病例(50.4%,67 例)为混合细胞性(MCCHL)亚型,30%(40 例)为结节硬化性(NSCCHL)亚型。与 HIV 相关的病例(60%,6 例)主要为 MCHL 亚型。4 年总生存率(OS)为 83.1%。早期患者的 4 年 OS 为 100%,低危(国际预后评分[IPS]≤2)和高危(IPS≥3)的晚期患者分别为 94.1%和 62.9%。所有接受联合治疗的患者均存活,而仅接受阿霉素、博来霉素、长春碱和达卡巴嗪治疗的患者 4 年 OS 率为 77.9%。
HL 影响埃塞俄比亚最年轻和最具生产力的人群。HIV 相关和非 HIV 相关 HL 的治疗结果均良好。然而,由于大多数埃塞俄比亚人无法获得专科治疗,研究人群可能是一个高度选择的群体。